Wim Wynendaele

1.2k total citations
25 papers, 696 citations indexed

About

Wim Wynendaele is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Wim Wynendaele has authored 25 papers receiving a total of 696 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 9 papers in Molecular Biology and 7 papers in Cancer Research. Recurrent topics in Wim Wynendaele's work include Cancer Treatment and Pharmacology (8 papers), HER2/EGFR in Cancer Research (5 papers) and Angiogenesis and VEGF in Cancer (5 papers). Wim Wynendaele is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), HER2/EGFR in Cancer Research (5 papers) and Angiogenesis and VEGF in Cancer (5 papers). Wim Wynendaele collaborates with scholars based in Belgium, France and Netherlands. Wim Wynendaele's co-authors include A.T. van Oosterom, Robert Paridaens, Hans Wildiers, Herlinde Dumez, Joachim Drevs, Jaap Verweij, Ronald Hoekstra, C. Brindley, Ferry A.L.M. Eskens and Sebastian Böttcher and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Wim Wynendaele

25 papers receiving 674 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wim Wynendaele Belgium 10 303 303 182 138 104 25 696
Takumi Shimomatsuya Japan 14 470 1.6× 387 1.3× 267 1.5× 285 2.1× 44 0.4× 51 1.0k
Jeanette Philips Australia 15 213 0.7× 218 0.7× 143 0.8× 95 0.7× 24 0.2× 23 829
Hamilto Yamamoto Brazil 14 157 0.5× 263 0.9× 176 1.0× 137 1.0× 53 0.5× 41 650
Peter Jindra United States 14 214 0.7× 97 0.3× 107 0.6× 67 0.5× 66 0.6× 39 966
Ping Han China 17 240 0.8× 168 0.6× 134 0.7× 166 1.2× 24 0.2× 67 791
Kenji Yorita Japan 14 260 0.9× 202 0.7× 126 0.7× 160 1.2× 17 0.2× 72 689
Makoto Toi Japan 17 340 1.1× 190 0.6× 158 0.9× 227 1.6× 21 0.2× 65 800
Tadao Takano Japan 20 238 0.8× 232 0.8× 112 0.6× 117 0.8× 16 0.2× 54 1.1k
A Fanucchi Italy 24 267 0.9× 420 1.4× 159 0.9× 181 1.3× 21 0.2× 64 1.6k
Konrad Ptaszyński Poland 16 184 0.6× 249 0.8× 170 0.9× 369 2.7× 48 0.5× 47 846

Countries citing papers authored by Wim Wynendaele

Since Specialization
Citations

This map shows the geographic impact of Wim Wynendaele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wim Wynendaele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wim Wynendaele more than expected).

Fields of papers citing papers by Wim Wynendaele

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wim Wynendaele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wim Wynendaele. The network helps show where Wim Wynendaele may publish in the future.

Co-authorship network of co-authors of Wim Wynendaele

This figure shows the co-authorship network connecting the top 25 collaborators of Wim Wynendaele. A scholar is included among the top collaborators of Wim Wynendaele based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wim Wynendaele. Wim Wynendaele is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Baldewijns, Marcella, Liesbeth De Wever, Maarten Albersen, et al.. (2023). Pseudoprogression and Mixed Responses in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab: A Retrospective Analysis. Clinical Genitourinary Cancer. 21(4). 442–451. 1 indexed citations
2.
Verbiest, Annelies, Evelyne Lerut, Marcella Baldewijns, et al.. (2020). Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors. Urologic Oncology Seminars and Original Investigations. 38(8). 686.e1–686.e9. 2 indexed citations
3.
Wynendaele, Wim, et al.. (2018). Real-world use of granulocyte colony-stimulating factor in ambulatory breast cancer patients: a cross-sectional study. Supportive Care in Cancer. 27(3). 1099–1108. 5 indexed citations
4.
Lintermans, Anneleen, Lynn Jongen, Diether Lambrechts, et al.. (2016). Prospective study evaluating the effect of impaired tamoxifen metabolisation on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting.. Journal of Clinical Oncology. 34(15_suppl). 523–523. 3 indexed citations
5.
6.
Wildiers, Hans, Christel Fontaine, Peter Vuylsteke, et al.. (2010). Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment. 123(2). 463–469. 39 indexed citations
7.
Wildiers, Hans, Patrick Neven, Marie‐Rose Christiaens, et al.. (2010). Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer. Annals of Oncology. 22(3). 588–594. 22 indexed citations
8.
Janus, Nicolas, Vincent Launay‐Vacher, J-P. Machiels, et al.. (2010). Cancer and renal insufficiency results of the BIRMA study. British Journal of Cancer. 103(12). 1815–1821. 133 indexed citations
9.
Saegeman, Veroniek, et al.. (2009). Transfusion‐induced serum sickness. Transfusion. 49(2). 372–345. 2 indexed citations
10.
Beuselinck, Benoit, Hans Wildiers, Wim Wynendaele, et al.. (2009). Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: A randomized phase-II study of the Belgian Society of Medical Oncology. Critical Reviews in Oncology/Hematology. 75(1). 70–77. 19 indexed citations
11.
Wynendaele, Wim, Joeri L. Aerts, Robert Paridaens, et al.. (2003). Real-time quantitative RT–PCR and detection of tumour cell dissemination in breast cancer patients: plasmid versus cell line dilutions. Annals of Oncology. 14(8). 1241–1245. 6 indexed citations
12.
Eskens, Ferry A.L.M., Herlinde Dumez, Ronald Hoekstra, et al.. (2003). Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours. European Journal of Cancer. 39(7). 917–926. 178 indexed citations
13.
Aerts, Joeri L., Wim Wynendaele, Robert Paridaens, et al.. (2001). A real-time quantitative reverse transcriptase polymerase chain reaction (RT–PCR) to detect breast carcinoma cells in peripheral blood. Annals of Oncology. 12(1). 39–46. 73 indexed citations
14.
Groen, Harry J.M., et al.. (2001). PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic study.. PubMed. 7(12). 3928–33. 12 indexed citations
15.
Landuyt, Willy, M. Drijkoningen, Sandra Nuyts, et al.. (2000). Vascular targeting of solid tumours. European Journal of Cancer. 36(14). 1833–1843. 60 indexed citations
16.
Wynendaele, Wim, et al.. (1999). Neoadjuvant chemotherapy with sequential doxorubicine (DOX) and docetaxel (DOC) in locally advanced breast cancer (LABC): a pilot study. 18. 5 indexed citations
17.
Wynendaele, Wim, Rita Derua, Marc Hoylaerts, et al.. (1999). Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: A key to study an angiogenic marker in vivo?. Annals of Oncology. 10(8). 965–971. 91 indexed citations
18.
Wynendaele, Wim & van Oosterom At. (1999). Neoadjuvant/primary chemotherapy in cancer treatment: what advantage?. PubMed. 9(3). 212–21. 1 indexed citations
19.
Wynendaele, Wim, Rita Derua, Marc Hoylaerts, et al.. (1998). Vascular endothelial growth factor (VEGF): Plasma is the place to be. Annals of Oncology. 9. 122–122. 2 indexed citations
20.
Wynendaele, Wim, et al.. (1998). Angiogenesis: possibilities for therapeutic interventions.. Pharmacy World & Science. 20(6). 225–235. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Takumi Shimomatsuya Breakdown of academic impact, for papers by Jeanette Philips Breakdown of academic impact, for papers by Hamilto Yamamoto Breakdown of academic impact, for papers by Peter Jindra Breakdown of academic impact, for papers by Ping Han Breakdown of academic impact, for papers by Kenji Yorita Breakdown of academic impact, for papers by Makoto Toi Breakdown of academic impact, for papers by Tadao Takano Breakdown of academic impact, for papers by A Fanucchi Breakdown of academic impact, for papers by Konrad Ptaszyński
Rankless by CCL
2026